Evotec SE (EVO) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you, George, and good day, good afternoon to all of you following our Q1 2025 results webcast today. Only three weeks after the presentation of our strategic review in April, we will be picking up on the discussions we had in the meantime with some of you. And with that, I think I can move on to slide two in the presentation. As usual, it's my duty to point to the disclaimer and the cautionary note regarding forward-looking statements, which you'll find on that slide. And with that, I hand over to Christian Wojcicki, our CEO, the floor is yours. Good afternoon and thank you for taking the time to dial in. During our last call on April 17th, we shared our revised strategy. We talked about our value creation levers. We explained the components of our midterm plan and we provided guidance for 2025. the latter based on our understanding of the current underlying market dynamics and Evotech-specific business development. Today, we will focus on Q1 results. Our group performance in Q1 was in line with our expectations and along what we indicated three weeks ago. Therefore, we'll keep today's presentation short. Nevertheless, we have earmarked sufficient time for the dialogue with you after the presentation. So let me start giving you an overview of the first quarter. Over the past couple of months, we have been able to close a few exciting deals. We are particularly proud of the news around our protein degradation collaboration with BMS, which has made further progress. We're expanding the number of high-value molecular glue degraders. I will get back to this topic a bit later, since this collaboration is an excellent showcase for how our strategy of technology leadership translates into superior business opportunities. Another highlight to mention is the reception o...